Le Lézard
Classified in: Health, Science and technology
Subject: TRI

New Study: Postoperative Pain Can Be Reduced by Using NOL Monitoring to Guide Analgesic Medication During Surgery

RAMAT GAN, Israel, Sept. 29, 2020 /PRNewswire/ -- A new study has found that monitoring pain response levels during surgery with NOL technology (Medasense, Ramat Gan, Israel) can help reduce postoperative pain. Exploring the potential use of NOL monitoring to help enhance recovery after surgery, the study demonstrated that patient pain scores after surgery were 33% lower when administration of pain medication during surgery was guided with NOL monitoring.


NOL monitoring by Medasense. Improves post operative pain.


"High pain scores following surgical procedures are common and are associated with poor patient outcomes; but on the other hand we know that excessive use of opioids administered during the surgery itself to prevent postoperative pain can cause other complications," explains Prof. Dahan of Leiden University Medical Center's Department of Anesthesiology, who led the study.

NOL monitoring provides a reliable index to objectively detect and quantify noxious stimuli during anaesthesia, when patients can't communicate, guiding the clinical team in tailored opioid dosing for each patient. Earlier studies have shown that the NOL index outperforms other indexes for monitoring of pain response to surgical stimuli and that NOL-guided analgesia resulted in reduced intraoperative opioid consumption, leading to fewer intraoperative hypotensive events.

The new study, just published in the British Journal of Anaesthesia (BJA)[1], followed 50 patients undergoing elective abdominal surgery in a two-center randomized controlled trial. The patients were randomly divided so that one group received NOL-guided analgesia dosing during the surgery and the control group received analgesics according to standard of care (based on hemodynamic monitoring). The study showed that while there was no increase in overall dosing in the NOL-guided group, the patients in that group reported less pain in the first 90 minutes compared to the control arm.

In addition, stress hormone levels (ACTH and cortisol) were on average up to 50% lower in the NOL-guided group, which clinically aligns with the lower pain response levels in those patients during surgery.

"Clinicians using NOL monitoring to guide analgesia are able to identify more accurately when a patient's pain response level rises and to tailor analgesic medication more accurately. As we found that opioid dosing overall was not different between the groups, we can confidently relate the difference in outcomes to the timing of individualized dosing as guided by the NOL monitor," Prof. Dahan concluded.

About Medasense and NOL Technology

Medasense (www.medasense.com) offers a breakthrough technology that enables clinicians to optimize and personalize pain control and avoid overmedication. Medasense's flagship product, the PMD-200tm with its NOL® index, is a unique platform that objectively monitors and quantifies the patient's pain response by means of artificial intelligence and a proprietary non-invasive sensor platform. 

The PMD-200 is used to optimize pain management in critical care and operating rooms settings, where patients are unable to communicate.

Clinical studies have demonstrated its impact on patient safety and outcomes, including opioid sparing.

The PMD-200 is distributed in Europe exclusively by Medtronic, is cleared for marketing also in Canada, Latin America, Israel and Australia, and enables connectivity with Philips patient monitors.

Watch Medasense's 1-minute video

1. Meijer, F., Honing, M., Roor, T., Toet, S., Calis, P., Olofsen, E., Martini, C., van Velzen, M., Aarts, L., Niesters, M., Boon, M., Dahan, A. (2020). Reduced postoperative pain using Nociception Level-guided fentanyl dosing during sevoflurane anaesthesia: a randomised controlled trial. British Journal of Anaesthesia, In Press. DOI: https://doi.org/10.1016/j.bja.2020.07.057.

Photo - https://mma.prnewswire.com/media/1281101/Medasense_PMD_200_NOL_Monitoring.jpg
Logo - https://mma.prnewswire.com/media/1169999/Medasense_Logo.jpg


Medasense Logo


For further information please contact:
Mira Sofer
VP Biz Dev & Marketing

These press releases may also interest you

at 20:35
In response to an increase in global demand for end-to-end customer service solutions, Uniphore, an early market leader in the Conversational Service Automation (CSA) space, and NTT DATA Services, a digital business and IT services leader, today...

at 20:30
Ghost Gaming, a premier gaming lifestyle brand focused on cultivating the best talent in video gaming, was acquired by a group of Atlanta-based investors who plan to relocate its headquarters and operations to Atlanta. The move will further establish...

at 20:00
NeuroSigma, Inc., a Los Angeles-based bioelectronics company focused on commercializing Trigeminal Nerve Stimulation (TNS) technology for treating neurological and neuropsychiatric disorders announces the publication on October 14, 2020 in the...

at 19:00
ADVA (ISIN: DE0005103006), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported final financial results for Q3 2020 ended on September 30, 2020. The results have been prepared in accordance with...

at 19:00
Panviva today announced Aurora Energy as a new customer for its cloud knowledge management solution. Aurora Energy, located in the Australian state of Tasmania, is the state's leading energy retailer and offers the most reliable electricity, gas, and...

at 19:00
Hitachi Solutions, a leading provider of global industry solutions powered by the Microsoft Cloud, is pleased to announce its inclusion in Forrester's Q4 2020 Now Tech report on Azure services providers. Hitachi Solutions was included among the cloud...

News published on 29 september 2020 at 03:30 and distributed by: